메뉴 건너뛰기




Volumn 92, Issue 10, 2013, Pages 1309-1318

De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): A contribution to the reopened "gO question"

Author keywords

AML; Ara C; Fludarabine; Gemtuzumab ozogamicin; Idarubicin

Indexed keywords

CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN;

EID: 84883871342     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1780-7     Document Type: Article
Times cited : (3)

References (43)
  • 3
    • 0018769877 scopus 로고
    • Daunorubicin cytosine arabinoside and 6-thioguanine (DAT) combination therapy for the treatment of acute non lymphocytic leukaemia
    • 10.1016/0145-2126(79)90012-2 1:STN:280:DyaE1M3ktlSgtA%3D%3D 470431
    • Amadori S, Papa G, Meloni G, Pacilli L, Mandelli F (1979) Daunorubicin cytosine arabinoside and 6-thioguanine (DAT) combination therapy for the treatment of acute non lymphocytic leukaemia. Leuk Res 3:147-152
    • (1979) Leuk Res , vol.3 , pp. 147-152
    • Amadori, S.1    Papa, G.2    Meloni, G.3    Pacilli, L.4    Mandelli, F.5
  • 5
    • 0025907179 scopus 로고
    • Results of a randomised trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukaemia
    • 1:STN:280:DyaK3M7pvVCqtw%3D%3D 2015395
    • Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J (1991) Results of a randomised trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukaemia. Blood 77:1666-1674
    • (1991) Blood , vol.77 , pp. 1666-1674
    • Berman, E.1    Heller, G.2    Santorsa, J.3    McKenzie, S.4    Gee, T.5    Kempin, S.6    Gulati, S.7    Andreeff, M.8    Kolitz, J.9    Gabrilove, J.10
  • 7
    • 79953702269 scopus 로고    scopus 로고
    • Treatment of unfit patients with acute myeloid leukemia: A still open clinical challenge
    • 10.3816/CLML.2011.n.001 1:CAS:528:DC%2BC3MXhtl2iu7vI 21454185
    • Ferrara F (2011) Treatment of unfit patients with acute myeloid leukemia: a still open clinical challenge. Clin Lymphoma Myeloma Leuk 11:10-16
    • (2011) Clin Lymphoma Myeloma Leuk , vol.11 , pp. 10-16
    • Ferrara, F.1
  • 8
    • 77950480200 scopus 로고    scopus 로고
    • Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: A combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M.D. Anderson Cancer Center study
    • 10.1200/JCO.2009.25.1066 20159819
    • Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR, Estey EH (2010) Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M.D. Anderson Cancer Center study. J Clin Oncol 28:1766-1771
    • (2010) J Clin Oncol , vol.28 , pp. 1766-1771
    • Walter, R.B.1    Kantarjian, H.M.2    Huang, X.3    Pierce, S.A.4    Sun, Z.5    Gundacker, H.M.6    Ravandi, F.7    Faderl, S.H.8    Tallman, M.S.9    Appelbaum, F.R.10    Estey, E.H.11
  • 10
    • 0027213870 scopus 로고
    • Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myeloid leukemia
    • 10.3109/10428199309148532 1:STN:280:DyaK3szltVGgtw%3D%3D 8394169
    • Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating M (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myeloid leukemia. Leuk Lymphoma 9:343-350
    • (1993) Leuk Lymphoma , vol.9 , pp. 343-350
    • Estey, E.1    Plunkett, W.2    Gandhi, V.3    Rios, M.B.4    Kantarjian, H.5    Keating, M.6
  • 17
    • 3242729315 scopus 로고    scopus 로고
    • First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients
    • 10.1016/j.leukres.2004.01.009 1:CAS:528:DC%2BD2cXlsVarsbc%3D 15234577
    • Piccaluga PP, Martinelli G, Rondoni M, Malagola M, Gaitani S, Visani G, Baccarani M (2004) First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 28:987-990
    • (2004) Leuk Res , vol.28 , pp. 987-990
    • Piccaluga, P.P.1    Martinelli, G.2    Rondoni, M.3    Malagola, M.4    Gaitani, S.5    Visani, G.6    Baccarani, M.7
  • 18
    • 77957711298 scopus 로고    scopus 로고
    • Preliminary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia
    • abstr 790
    • Petersdorf S, Kopecky K, Stuart RK, Larson RA, Nevill TJ, Stenke L, Slovak ML, Tallman MS, Willman CL, Erba H, Appelbaum FR (2009) Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 114:326-327, abstr 790
    • (2009) Blood , vol.114 , pp. 326-327
    • Petersdorf, S.1    Kopecky, K.2    Stuart, R.K.3    Larson, R.A.4    Nevill, T.J.5    Stenke, L.6    Slovak, M.L.7    Tallman, M.S.8    Willman, C.L.9    Erba, H.10    Appelbaum, F.R.11
  • 19
    • 79952099282 scopus 로고    scopus 로고
    • Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial
    • 10.1200/JCO.2010.31.4310 1:CAS:528:DC%2BC3MXivFWmsrY%3D 21172891
    • Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, Yin JA, Hunter A, Goldstone AH, Wheatley K (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 29:369-377
    • (2011) J Clin Oncol , vol.29 , pp. 369-377
    • Burnett, A.K.1    Hills, R.K.2    Milligan, D.3    Kjeldsen, L.4    Kell, J.5    Russell, N.H.6    Yin, J.A.7    Hunter, A.8    Goldstone, A.H.9    Wheatley, K.10
  • 22
    • 34250823073 scopus 로고    scopus 로고
    • Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: Results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients
    • 10.1111/j.1365-2141.2007.06646.x 1:CAS:528:DC%2BD2sXptFGgtb8%3D 17593025
    • Clavio M, Vignolo L, Albarello A, Varaldo R, Pierri I, Catania G, Balocco M, Michelis G, Miglino M, Manna A, Balleari E, Carella AM, Sessarego M, Van Lint MT, Bacigalupo A, Gobbi M (2007) Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 138:186-195
    • (2007) Br J Haematol , vol.138 , pp. 186-195
    • Clavio, M.1    Vignolo, L.2    Albarello, A.3    Varaldo, R.4    Pierri, I.5    Catania, G.6    Balocco, M.7    Michelis, G.8    Miglino, M.9    Manna, A.10    Balleari, E.11    Carella, A.M.12    Sessarego, M.13    Van Lint, M.T.14    Bacigalupo, A.15    Gobbi, M.16
  • 23
    • 0035469883 scopus 로고    scopus 로고
    • The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1,065 patients entered into the United Kingdom Medical Research Council AML11 trial
    • Medical Research Council Adult Leukemia Working Party 10.1182/blood.V98.5.1312 1:CAS:528:DC%2BD3MXmvFGjtrw%3D 11520776
    • Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH, Medical Research Council Adult Leukemia Working Party (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1,065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320
    • (2001) Blood , vol.98 , pp. 1312-1320
    • Grimwade, D.1    Walker, H.2    Harrison, G.3    Oliver, F.4    Chatters, S.5    Harrison, C.J.6    Wheatley, K.7    Burnett, A.K.8    Goldstone, A.H.9
  • 25
    • 0025760557 scopus 로고
    • Mitoxantrone, etoposide, and intermediate-dose cytarabine: An effective and tolerable regimen for the treatment of refractory acute myeloid leukaemia
    • 1:STN:280:DyaK3M3lvFWksA%3D%3D 2045861
    • Amadori S, Arcese W, Isacchi G, Meloni G, Petti MC, Monarca B, Testi AM, Mandelli F (1991) Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukaemia. J Clin Oncol 9:1210-1214
    • (1991) J Clin Oncol , vol.9 , pp. 1210-1214
    • Amadori, S.1    Arcese, W.2    Isacchi, G.3    Meloni, G.4    Petti, M.C.5    Monarca, B.6    Testi, A.M.7    Mandelli, F.8
  • 26
    • 0033063039 scopus 로고    scopus 로고
    • GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly
    • 1:STN:280:DyaK1M3pvFegtw%3D%3D 10366806
    • Pierri I, Clavio M, Miglino M, Cavaliere M, Pietrasanta D, Gobbi M (1999) GM-IVA, a short induction course for de novo acute myeloid leukemia, suitable for the elderly. Haematologica 84:562-563
    • (1999) Haematologica , vol.84 , pp. 562-563
    • Pierri, I.1    Clavio, M.2    Miglino, M.3    Cavaliere, M.4    Pietrasanta, D.5    Gobbi, M.6
  • 28
    • 0037217782 scopus 로고    scopus 로고
    • Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukaemia
    • 10.1007/s00280-002-0546-z 1:CAS:528:DC%2BD3sXhtlGrtg%3D%3D 12497211
    • Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ (2003) Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukaemia. Cancer Chemother Pharmacol 51:87-90
    • (2003) Cancer Chemother Pharmacol , vol.51 , pp. 87-90
    • Alvarado, Y.1    Tsimberidou, A.2    Kantarjian, H.3    Cortes, J.4    Garcia-Manero, G.5    Faderl, S.6    Thomas, D.7    Estey, E.8    Giles, F.J.9
  • 31
    • 84869401307 scopus 로고    scopus 로고
    • High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk
    • 10.1016/j.clml.2012.05.007 1:CAS:528:DC%2BC38XhslWqtbjJ 23017331
    • Tavor S, Rahamim E, Sarid N, Rozovski U, Gibstein L, Aviv F, Kirsner I, Naparstek E (2012) High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk. Clin Lymphoma Myeloma Leuk 12:438-443
    • (2012) Clin Lymphoma Myeloma Leuk , vol.12 , pp. 438-443
    • Tavor, S.1    Rahamim, E.2    Sarid, N.3    Rozovski, U.4    Gibstein, L.5    Aviv, F.6    Kirsner, I.7    Naparstek, E.8
  • 32
    • 84864225484 scopus 로고    scopus 로고
    • Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast-phase chronic myeloid leukemia
    • 10.1016/j.clml.2012.03.003 1:CAS:528:DC%2BC38XhtV2ntbrE 22534616
    • Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H (2012) Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast-phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 12:244-251
    • (2012) Clin Lymphoma Myeloma Leuk , vol.12 , pp. 244-251
    • Jabbour, E.1    Garcia-Manero, G.2    Cortes, J.3    Ravandi, F.4    Plunkett, W.5    Gandhi, V.6    Faderl, S.7    O'Brien, S.8    Borthakur, G.9    Kadia, T.10    Burger, J.11    Konopleva, M.12    Brandt, M.13    Huang, X.14    Kantarjian, H.15
  • 35
    • 0038015273 scopus 로고    scopus 로고
    • Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia
    • 10.1016/S0145-2126(03)00021-3 1:CAS:528:DC%2BD3sXltF2js7k%3D 12860007
    • Apostolidou E, Cortes J, Tsimberidou A, Estey E, Kantarjian H, Giles FJ (2003) Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 27:887-891
    • (2003) Leuk Res , vol.27 , pp. 887-891
    • Apostolidou, E.1    Cortes, J.2    Tsimberidou, A.3    Estey, E.4    Kantarjian, H.5    Giles, F.J.6
  • 38
    • 0031005627 scopus 로고    scopus 로고
    • Acute myeloid leukemia in the elderly: Assessment of multidrugs resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct response to standard chemotherapy: A Southwest Oncology Group study
    • 1:CAS:528:DyaK2sXivVymsro%3D 9129038
    • Leith CP, Kopechy KJ, Godwin J, McConnel T, Slovak ML, Ming CI, Head DR, Appelbaum FR, Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrugs resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct response to standard chemotherapy: a Southwest Oncology Group study. Blood 89:3323-3329
    • (1997) Blood , vol.89 , pp. 3323-3329
    • Leith, C.P.1    Kopechy, K.J.2    Godwin, J.3    McConnel, T.4    Slovak, M.L.5    Ming, C.I.6    Head, D.R.7    Appelbaum, F.R.8    Willman, C.L.9
  • 39
    • 64149100530 scopus 로고    scopus 로고
    • Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
    • United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup 10.1111/j.1365-2141.2009.07663.x 19344426
    • Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, Moorman AV, Burnett AK, United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup (2009) Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 145:598-605
    • (2009) Br J Haematol , vol.145 , pp. 598-605
    • Wheatley, K.1    Brookes, C.L.2    Howman, A.J.3    Goldstone, A.H.4    Milligan, D.W.5    Prentice, A.G.6    Moorman, A.V.7    Burnett, A.K.8
  • 41
    • 23744444913 scopus 로고    scopus 로고
    • Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta analysis
    • 10.1038/sj.leu.2403838 1:CAS:528:DC%2BD2MXmtlSjsL0%3D 15959528
    • Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T (2005) Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta analysis. Leukemia 19:1345-1349
    • (2005) Leukemia , vol.19 , pp. 1345-1349
    • Yanada, M.1    Matsuo, K.2    Suzuki, T.3    Kiyoi, H.4    Naoe, T.5
  • 42
    • 84859903057 scopus 로고    scopus 로고
    • Treatment of AML: Resurrection for gemtuzumab ozogamicin?
    • 10.1016/S0140-6736(12)60534-0 22482941
    • Estey E (2012) Treatment of AML: resurrection for gemtuzumab ozogamicin? Lancet 379:1468-1469
    • (2012) Lancet , vol.379 , pp. 1468-1469
    • Estey, E.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.